Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
28 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
AbGenomics International, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AbGenomics International, Inc. - Product Pipeline Review - 2014', provides an overview of the AbGenomics International, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of AbGenomics International, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of AbGenomics International, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of AbGenomics International, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the AbGenomics International, Inc.'s pipeline products Reasons to buy - Evaluate AbGenomics International, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of AbGenomics International, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the AbGenomics International, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of AbGenomics International, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of AbGenomics International, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of AbGenomics International, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 AbGenomics International, Inc. Snapshot 5 AbGenomics International, Inc. Overview 5 Key Information 5 Key Facts 5 AbGenomics International, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 AbGenomics International, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 AbGenomics International, Inc. - Pipeline Products Glance 10 AbGenomics International, Inc. - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Phase I Products/Combination Treatment Modalities 11 AbGenomics International, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 AbGenomics International, Inc. - Drug Profiles 13 AbGn-168H 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 AbGn-7 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 AbGn-107 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 AbGn-108 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 AbGn-109 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 AbGn-110 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 AbGn-122 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 AbGenomics International, Inc. - Pipeline Analysis 21 AbGenomics International, Inc. - Pipeline Products by Target 21 AbGenomics International, Inc. - Pipeline Products by Route of Administration 22 AbGenomics International, Inc. - Pipeline Products by Molecule Type 23 AbGenomics International, Inc. - Recent Pipeline Updates 24 AbGenomics International, Inc. - Dormant Projects 25 AbGenomics International, Inc. - Locations And Subsidiaries 26 Head Office 26 Other Locations & Subsidiaries 26 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 28 Disclaimer 28
List of Tables AbGenomics International, Inc., Key Information 5 AbGenomics International, Inc., Key Facts 5 AbGenomics International, Inc. - Pipeline by Indication, 2014 7 AbGenomics International, Inc. - Pipeline by Stage of Development, 2014 8 AbGenomics International, Inc. - Monotherapy Products in Pipeline, 2014 9 AbGenomics International, Inc. - Phase II, 2014 10 AbGenomics International, Inc. - Phase I, 2014 11 AbGenomics International, Inc. - Preclinical, 2014 12 AbGenomics International, Inc. - Pipeline by Target, 2014 21 AbGenomics International, Inc. - Pipeline by Route of Administration, 2014 22 AbGenomics International, Inc. - Pipeline by Molecule Type, 2014 23 AbGenomics International, Inc. - Recent Pipeline Updates, 2014 24 AbGenomics International, Inc. - Dormant Developmental Projects,2014 25 AbGenomics International, Inc., Other Locations 26
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.